ストックスクリーナーアプリを入手
8.71
3.69%
0.31
アフターアワーズ：
8.69
-0.02
-0.23%
前日終値:
$8.40
開ける：
$8.4
24時間の取引高:
12,956
Relative Volume:
0.21
時価総額：
$93.93M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+8.88%
1か月 パフォーマンス:
+6.87%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$8.342
$8.71
1週間の範囲:
$8.0595
$9.10
52週間の値動き範囲:
$7.24
$17.96
Imagenebio Inc Stock (IMA) Company Profile
IMA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMA
Imagenebio Inc
|
8.71 | 93.93M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Imagenebio Inc Stock (IMA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-24 | 開始されました | Leerink Partners | Outperform |
Imagenebio Inc (IMA) 最新ニュース
ImageneBio, Inc. (NASDAQ:IMA) Short Interest Update - Defense World
Miragene Inc. Announces Extension of Key Service Agreement - MarketScreener
Imagenebio Inc elects not to renew agreement with MirageneSEC filing - MarketScreener
ImageneBio IncOn Oct 23, Elects Not To Renew Agreement With MirageneSEC Filing - TradingView
ImageneBio Extends Agreement with Miragene Inc. - TipRanks
Leerink Partners initiates Imagene Bio stock with Outperform rating By Investing.com - Investing.com South Africa
Leerink Partners initiates Imagene Bio stock with Outperform rating - Investing.com India
Leerink Partners Initiates ImageneBio at Outperform With $30 Price Target - MarketScreener
This Albemarle Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Leerink Partners Initiates Coverage on ImageneBio (IMA) with Out - GuruFocus
ImageneBio’s IMG-007: A Promising Blockbuster in Atopic Dermatitis with Strategic Leadership and Competitive Edge - TipRanks
ImageneBio initiated with an Outperform at Leerink - TipRanks
Weiss Ratings Initiates Coverage on ImageneBio (NASDAQ:IMA) - Defense World
ImageneBio, Inc.Common Stock (Nasdaq:IMA) Stock Quote - FinancialContent
ImageneBio appoints CEO Kristin Yarema as interim principal financial officer By Investing.com - Investing.com Nigeria
ImageneBio, Inc. Appoints Kristin Yarema as Interim Principal Financial Officer, Effective October 21, 2025 - MarketScreener
ImageneBio appoints CEO Kristin Yarema as interim principal financial officer - Investing.com
ImageneBio Appoints New Interim Financial Officer - TipRanks
OX40 Targeted Therapy Clinical Trials Anti OX40 Antibody Development Market Opportunity Insight 2026 - GlobeNewswire Inc.
ImageneBio CFO Jotin Marango resigns, company to begin search for successor - Investing.com Australia
ImageneBio Charts New Course Following Merger Completion - AD HOC NEWS
ImageneBio CFO Resignation Announced - TipRanks
ImageneBio (NASDAQ:IMA) Cut to “Hold” at Zacks Research - Defense World
Wall Street Zen Upgrades ImageneBio (NASDAQ:IMA) to Hold - Defense World
Ikena Oncology shares climb as Kristin Yarema named CEO of soon-to-merge ImageneBio - msn.com
ImageneBio (NASDAQ:IMA) Stock Price Down 1.2% – Here’s Why - Defense World
ImageneBio files to sell 2.51M shares of common stock for holders - MSN
ImageneBio (NASDAQ:IMA) Shares Down 1.3%Should You Sell? - MarketBeat
ImageneBio (NASDAQ:IMA) Shares Down 1.3% – Should You Sell? - Defense World
HUTCHMED Reports 2025 Interim Results - GlobeNewswire
Ikena Oncology (IMA) Projected to Post Quarterly Earnings on Thursday - Defense World
Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade - MSN
Q3 EPS Estimates for Ikena Oncology Lifted by William Blair - Defense World
William Blair Comments on Ikena Oncology FY2029 Earnings - Defense World
ImageneBio Approves 2025 Inducement Plan for Employees - The Globe and Mail
ImageneBio board approves 2025 inducement plan for new employee equity awards - Investing.com Australia
ImagenBio Adopts 2025 Equity Inducement Plan to Retain Top Talent - AInvest
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ImageneBio Grants Massive $9.6M Equity Package: New CEO Gets 436K Stock Options, 153K RSUs - Stock Titan
Imagenebio shares rise 7.26% premarket after insider bought shares worth $7.999.924. - AInvest
Insider Transactions Reported | ImageneBio(IMA)saw insider trading activity on 7/30/2025 - AInvest
Ikena Oncology Completes Merger, Becomes ImageneBio, Inc. - The Globe and Mail
Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Ikena Oncology Inc. (NASDAQ: IKNA) - MarketScreener
IMA Stock Price and Chart — NASDAQ:IMA - TradingView
ImageneBio Appoints Kristin Yarema as CEO, Merges with Ikena Oncology, Raises $75M - AInvest
Imagenebio Inc (IMA) 財務データ
Imagenebio Inc (IMA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.62%
0.21%
大文字化:
|
ボリューム (24 時間):